Junhui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Junhui Wang has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Hongxing Wang
Department of Neurology, Xuanwu Hospital, Capital Medical University
5 shared publications - Zhiguo Ding
Department of Thyropathy, Dongzhimen Hospital, Beijing University of Chinese Medicine
4 shared publications - Jingwei Zhou
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
3 shared publications - Xin’ai Li
Department of Thyropathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
3 shared publications - Daiquan Gao
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publications - Dirk Matthias Hermann
Department of Neurology, University Hospital Essen, University of Duisburg-Essen
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1896060
Research progress on the association between Hashimoto’s thyroiditis and autoimmune encephalitis: a review
Hashimoto’s thyroiditis (HT), which is the most common autoimmune thyroid disease, has, in recent times, been the subject of growing interest because of its possible link with autoimmune encephalitis (AE). This overview comprehensively reviews the epidemiological connections, shared immunopathological mechanisms, common clinical manifestations, diagnostic issues, and treatment methods of HT and AE. By combining the most recent progress in immunology, brain imaging, and clinical studies, we analyze the similarities and differences between HT-associated encephalopathy, commonly identified as Hashimoto’s encephalopathy, and the standard types of AE. Despite these advances, diagnostic and therapeutic challenges remain in patients who show neurological symptoms in the context of HT. The aim of this paper was to enhance the knowledge of clinicians about the connection between these two autoimmune disorders, normalize diagnostic procedures, and update treatment methods in order to achieve better patient results. Furthermore, this paper outlines some of the directions for future work that would help reveal mechanisms and develop clinical management.
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1896060
Open AccessResearch progress on the association between Hashimoto’s thyroiditis and autoimmune encephalitis: a review
Hashimoto’s thyroiditis (HT), which is the most common autoimmune thyroid disease, has, in recent times, been the subject of growing interest because of its possible link with autoimmune encephalitis (AE). This overview comprehensively reviews the epidemiological connections, shared immunopathological mechanisms, common clinical manifestations, diagnostic issues, and treatment methods of HT and AE. By combining the most recent progress in immunology, brain imaging, and clinical studies, we analyze the similarities and differences between HT-associated encephalopathy, commonly identified as Hashimoto’s encephalopathy, and the standard types of AE. Despite these advances, diagnostic and therapeutic challenges remain in patients who show neurological symptoms in the context of HT. The aim of this paper was to enhance the knowledge of clinicians about the connection between these two autoimmune disorders, normalize diagnostic procedures, and update treatment methods in order to achieve better patient results. Furthermore, this paper outlines some of the directions for future work that would help reveal mechanisms and develop clinical management.
- Open Access
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 20, 1908534
Editorial: Emerging mechanisms in neuroinflammation: potential therapeutic targets for neurodegenerative diseases
Neuroinflammatory responses are triggered and sustained by a diverse array of signaling molecules, including damage-associated molecular patterns (DAMPs), cytokines, chemokines, reactive oxygen species, and other inflammatory mediators (García-Domínguez et al., 2025). While acute inflammatory responses may initially serve protective functions by promoting tissue repair and the clearance of cellular debris, chronic or dysregulated neuroinflammation can become detrimental, amplifying neuronal damage and accelerating disease progression. Advances in transcriptomic, proteomic, and single-cell technologies have further revealed remarkable heterogeneity among glial and immune cell populations, highlighting the complexity of inflammatory signaling networks within the diseased nervous system.The cyclic GMP-AMP synthase (cGAS) is a cytosolic pattern recognition sensor that detects cytosolic DNA derived from pathogens or damaged host cells. Upon recognizing doublestranded DNA, cGAS generates the second messenger cGAMP, which activates downstream inflammatory signaling pathways, including type I interferon responses. By sensing both exogenous and endogenous DNA, such as mitochondrial and nuclear DNA released during cellular stress, the cGAS pathway serves as a critical mediator of innate immunity and neuroinflammation (Yu et al., 2021). A recent study has suggested the role of global cGAS-STING signaling in various neurological and neuroinflammatory diseases and the potential contribution of cGAS-STING to neurodegenerative diseases via brain endothelial cells (Sun et al., 2024).Over the past decade, substantial progress has been made in elucidating the molecular and cellular pathways that govern neuroinflammatory processes. These discoveries have uncovered numerous potential therapeutic targets, including inflammatory signaling cascades, immune cell activation states, metabolic pathways, and mechanisms of intercellular communication. Nevertheless, many fundamental questions remain regarding the precise roles of neuroinflammation during different stages of disease progression and the extent to which specific inflammatory pathways may be exploited for therapeutic benefit.Targets for Neurodegenerative Diseases, aims to provide a comprehensive overview of recent advances in our understanding of neuroinflammatory mechanisms and their implications for neurodegenerative disorders. By bringing together contributions from diverse fields, including neuroscience, immunology, molecular biology, and translational medicine, this collection highlights novel insights into the complex interactions between the nervous and immune systems and explores emerging strategies for therapeutic intervention. 9 publications are included in the collection with 5 review articles and 4 original research articles.In their study, Paldino et al. investigated the role of the CD47-SIRPα signaling pathway in HD, a pathway known to regulate immune responses and phagocytosis (Paldino et al., 2024). The authors found that CD47 expression was reduced in striatal neurons of HD mice, whereas SIRPα expression was increased. Disruption of CD47-SIRPα signaling was associated with decreased activation of the phosphatase SHP-1 and increased neuronal STAT1 expression, suggesting enhanced inflammatory signaling. These findings identify impaired CD47-SIRPα-mediated regulation of neuroinflammation as a potential contributor to neuronal damage in HD and highlight this pathway as a possible therapeutic target for neuroprotection.In a large cohort of patients with multiple system atrophy (MSA), Chen et al. examined the relationship between circulating inflammatory cytokines and clinical manifestations (Chen et al. 2024). They found that serum TNF-α levels were significantly elevated in MSA patients compared with healthy controls and showed a moderate diagnostic value for distinguishing MSA from controls. Both TNF-α and IL-6 were associated with anxiety symptoms, while IL-6 was additionally linked to disease severity and functional impairment. These findings support a role for peripheral inflammation in MSA pathogenesis and suggest that TNF-α may serve as a potential biomarker for disease identification.Another study led by Park et al. investigated the therapeutic potential of near-infrared photobiomodulation (PBM) in a scopolamine-induced model of Alzheimer's disease-like cognitive impairment (Park et al., 2024). PBM improved learning and memory performance, reduced neuronal cell death in the hippocampus, and modulated MAPK signaling and astrocyte activation. These findings suggest that PBM may exert neuroprotective effects through the regulation of neuroinflammatory pathways and astrocyte function, highlighting a promising noninvasive therapeutic approach for neurodegenerative disorders.A study established a novel tri-culture model comprising vascular endothelial cells, neurons, and microglia to investigate the mechanisms underlying hypertension-related depression (HD) (Zhao et al., 2025). The model successfully recapitulated key pathological features observed in HD, including endothelial dysfunction, neuroinflammation, neuronal injury, microglial activation, and disturbances in monoamine neurotransmitters. Mechanistically, these changes were associated with activation of the TLR4/NF-κB inflammatory pathway. By mimicking the interactions between vascular and neural components, this in vitro model provides a valuable platform for studying neuroinflammatory processes and evaluating potential therapeutic strategies for HD.In addition to the research articles, we collected 4 review articles as well. Research on neuroinflammation in Parkinson's disease has expanded rapidly, identifying microglial activation, oxidative stress, α-synuclein pathology, and gut-brain interactions as key drivers of disease progression (Chen et al., 2026). Mitochondrial dysfunction, lysosomal impairment, and...
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 20, 1908534
Open AccessEditorial: Emerging mechanisms in neuroinflammation: potential therapeutic targets for neurodegenerative diseases
Neuroinflammatory responses are triggered and sustained by a diverse array of signaling molecules, including damage-associated molecular patterns (DAMPs), cytokines, chemokines, reactive oxygen species, and other inflammatory mediators (García-Domínguez et al., 2025). While acute inflammatory responses may initially serve protective functions by promoting tissue repair and the clearance of cellular debris, chronic or dysregulated neuroinflammation can become detrimental, amplifying neuronal damage and accelerating disease progression. Advances in transcriptomic, proteomic, and single-cell technologies have further revealed remarkable heterogeneity among glial and immune cell populations, highlighting the complexity of inflammatory signaling networks within the diseased nervous system.The cyclic GMP-AMP synthase (cGAS) is a cytosolic pattern recognition sensor that detects cytosolic DNA derived from pathogens or damaged host cells. Upon recognizing doublestranded DNA, cGAS generates the second messenger cGAMP, which activates downstream inflammatory signaling pathways, including type I interferon responses. By sensing both exogenous and endogenous DNA, such as mitochondrial and nuclear DNA released during cellular stress, the cGAS pathway serves as a critical mediator of innate immunity and neuroinflammation (Yu et al., 2021). A recent study has suggested the role of global cGAS-STING signaling in various neurological and neuroinflammatory diseases and the potential contribution of cGAS-STING to neurodegenerative diseases via brain endothelial cells (Sun et al., 2024).Over the past decade, substantial progress has been made in elucidating the molecular and cellular pathways that govern neuroinflammatory processes. These discoveries have uncovered numerous potential therapeutic targets, including inflammatory signaling cascades, immune cell activation states, metabolic pathways, and mechanisms of intercellular communication. Nevertheless, many fundamental questions remain regarding the precise roles of neuroinflammation during different stages of disease progression and the extent to which specific inflammatory pathways may be exploited for therapeutic benefit.Targets for Neurodegenerative Diseases, aims to provide a comprehensive overview of recent advances in our understanding of neuroinflammatory mechanisms and their implications for neurodegenerative disorders. By bringing together contributions from diverse fields, including neuroscience, immunology, molecular biology, and translational medicine, this collection highlights novel insights into the complex interactions between the nervous and immune systems and explores emerging strategies for therapeutic intervention. 9 publications are included in the collection with 5 review articles and 4 original research articles.In their study, Paldino et al. investigated the role of the CD47-SIRPα signaling pathway in HD, a pathway known to regulate immune responses and phagocytosis (Paldino et al., 2024). The authors found that CD47 expression was reduced in striatal neurons of HD mice, whereas SIRPα expression was increased. Disruption of CD47-SIRPα signaling was associated with decreased activation of the phosphatase SHP-1 and increased neuronal STAT1 expression, suggesting enhanced inflammatory signaling. These findings identify impaired CD47-SIRPα-mediated regulation of neuroinflammation as a potential contributor to neuronal damage in HD and highlight this pathway as a possible therapeutic target for neuroprotection.In a large cohort of patients with multiple system atrophy (MSA), Chen et al. examined the relationship between circulating inflammatory cytokines and clinical manifestations (Chen et al. 2024). They found that serum TNF-α levels were significantly elevated in MSA patients compared with healthy controls and showed a moderate diagnostic value for distinguishing MSA from controls. Both TNF-α and IL-6 were associated with anxiety symptoms, while IL-6 was additionally linked to disease severity and functional impairment. These findings support a role for peripheral inflammation in MSA pathogenesis and suggest that TNF-α may serve as a potential biomarker for disease identification.Another study led by Park et al. investigated the therapeutic potential of near-infrared photobiomodulation (PBM) in a scopolamine-induced model of Alzheimer's disease-like cognitive impairment (Park et al., 2024). PBM improved learning and memory performance, reduced neuronal cell death in the hippocampus, and modulated MAPK signaling and astrocyte activation. These findings suggest that PBM may exert neuroprotective effects through the regulation of neuroinflammatory pathways and astrocyte function, highlighting a promising noninvasive therapeutic approach for neurodegenerative disorders.A study established a novel tri-culture model comprising vascular endothelial cells, neurons, and microglia to investigate the mechanisms underlying hypertension-related depression (HD) (Zhao et al., 2025). The model successfully recapitulated key pathological features observed in HD, including endothelial dysfunction, neuroinflammation, neuronal injury, microglial activation, and disturbances in monoamine neurotransmitters. Mechanistically, these changes were associated with activation of the TLR4/NF-κB inflammatory pathway. By mimicking the interactions between vascular and neural components, this in vitro model provides a valuable platform for studying neuroinflammatory processes and evaluating potential therapeutic strategies for HD.In addition to the research articles, we collected 4 review articles as well. Research on neuroinflammation in Parkinson's disease has expanded rapidly, identifying microglial activation, oxidative stress, α-synuclein pathology, and gut-brain interactions as key drivers of disease progression (Chen et al., 2026). Mitochondrial dysfunction, lysosomal impairment, and...
- Open Access
- 13 May 2026
- Published by Springer Nature in Nature
- Vol. 655 (8122) , 418-428
An X-linked long non-coding RNA, PTCHD1-AS, and the core features of autism
There are around 100 genes or copy-number variations used in genetic testing for autism spectrum disorder (ASD)1,2. The established genes are protein coding, and the associated phenotypes usually extend beyond sociobehavioural traits seen in autism, including cognitive/medical complexities and attention deficit hyperactivity disorder (ADHD)3,4. We examined whole-genome sequencing data in cases of ASD (9,349) and controls (8,332) and identify 27 male individuals with ASD with X-chromosome microdeletions that implicate the long non-coding RNA PTCHD1-AS as an ASD-susceptibility gene (odds ratio = 2.56, P = 0.01). Two Ptchd1-as-knockout mouse models, which were created by disrupting/deleting the evolutionarily conserved exon 3, show ASD-like features in male mice, including increased repetitive behaviours and impaired social behaviour and communication without cognitive comorbidities or ADHD-like behaviours. Hippocampus-dependent synaptic function, complex learning and locomotor activity are unaffected in knockout mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from postnatal day 7 onwards in the dorsal striatum, a predominantly GABAergic brain region that is implicated in ASD5. Multi-omics analysis revealed transcriptomic alterations in striatal oligodendrocytes, astrocytes and neurons impacting myelination and synaptic plasticity. Disrupting Ptchd1-as led to reductions in conventional protein kinase C (cPKC) isoforms, altered SRC and GSK-3α/β phosphorylation and enhanced striatal synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit-level dysregulation through PTCHD1-AS in ASD aetiology.
- 13 May 2026
- Published by Springer Nature in Nature
- Vol. 655 (8122) , 418-428
Open AccessAn X-linked long non-coding RNA, PTCHD1-AS, and the core features of autism
There are around 100 genes or copy-number variations used in genetic testing for autism spectrum disorder (ASD)1,2. The established genes are protein coding, and the associated phenotypes usually extend beyond sociobehavioural traits seen in autism, including cognitive/medical complexities and attention deficit hyperactivity disorder (ADHD)3,4. We examined whole-genome sequencing data in cases of ASD (9,349) and controls (8,332) and identify 27 male individuals with ASD with X-chromosome microdeletions that implicate the long non-coding RNA PTCHD1-AS as an ASD-susceptibility gene (odds ratio = 2.56, P = 0.01). Two Ptchd1-as-knockout mouse models, which were created by disrupting/deleting the evolutionarily conserved exon 3, show ASD-like features in male mice, including increased repetitive behaviours and impaired social behaviour and communication without cognitive comorbidities or ADHD-like behaviours. Hippocampus-dependent synaptic function, complex learning and locomotor activity are unaffected in knockout mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from postnatal day 7 onwards in the dorsal striatum, a predominantly GABAergic brain region that is implicated in ASD5. Multi-omics analysis revealed transcriptomic alterations in striatal oligodendrocytes, astrocytes and neurons impacting myelination and synaptic plasticity. Disrupting Ptchd1-as led to reductions in conventional protein kinase C (cPKC) isoforms, altered SRC and GSK-3α/β phosphorylation and enhanced striatal synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit-level dysregulation through PTCHD1-AS in ASD aetiology.
- Open Access
- 26 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 464
New Advances in Neuroimmunology and Neuroinflammation
The field of neuroimmunology has changed dramatically over the last ten years
- 26 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 464
Open AccessNew Advances in Neuroimmunology and Neuroinflammation
The field of neuroimmunology has changed dramatically over the last ten years
- Open Access
- 1 March 2026
- Published by KEAI Publishing in NeuroMarkers
- Vol. 3 (1)
Roles of circular RNAs targeted to synapses: Narrative review of potential mechanisms and biomarkers
- 1 March 2026
- Published by KEAI Publishing in NeuroMarkers
- Vol. 3 (1)
Open AccessRoles of circular RNAs targeted to synapses: Narrative review of potential mechanisms and biomarkers
- Open Access
- 14 February 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (2) , 229
Emerging Roles, Mechanisms, and Therapeutic Potential of Thyroid Hormones in Neurodegenerative Diseases: A Review
Thyroid hormones (THs) are master controllers in the endocrine system and have drawn considerable attention from the research community due to their associations with neurodegenerative diseases as well. In this review article, we present a comprehensive summary of the physiological functions and pathogenic mechanisms of THs in the regulation of several representative neurodegenerative diseases. Our study particularly focuses on Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). AD is the most common cause of dementia, primarily caused by tau protein tangles inside nerve cells and β-amyloid plaques outside, which lead to nerve cell death and brain atrophy. PD is primarily a movement disorder. The degeneration of dopaminergic neurons in the brain impairs the brain’s control over muscle activity. MS is usually considered to be an autoimmune demyelinating disease, but it has been found that MS also presents with secondary neurodegenerative pathology, including axonal loss and neuronal damage. In this review, the effects of TH on the pathogeneses of AD, PD, and MS are discussed in detail, with a focus on the following potential mechanisms: neuroprotection, neurogenesis, oxidative stress, and inflammatory response. In addition, we conduct an in-depth review of the possible clinical applications of TH, TH analogs, and thyrotropin-releasing hormone (TRH) in the treatment of AD, PD, and MS based on recent preclinical and clinical studies. By integrating experimental, clinical, and epidemiological results on the effects of TH on neurodegeneration, the present review constructs a theoretical basis for the involvement of TH in the pathogeneses of these diseases in detail. We believe that this basis will be useful for clinical diagnosis and treatment.
- 14 February 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (2) , 229
Open AccessEmerging Roles, Mechanisms, and Therapeutic Potential of Thyroid Hormones in Neurodegenerative Diseases: A Review
Thyroid hormones (THs) are master controllers in the endocrine system and have drawn considerable attention from the research community due to their associations with neurodegenerative diseases as well. In this review article, we present a comprehensive summary of the physiological functions and pathogenic mechanisms of THs in the regulation of several representative neurodegenerative diseases. Our study particularly focuses on Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). AD is the most common cause of dementia, primarily caused by tau protein tangles inside nerve cells and β-amyloid plaques outside, which lead to nerve cell death and brain atrophy. PD is primarily a movement disorder. The degeneration of dopaminergic neurons in the brain impairs the brain’s control over muscle activity. MS is usually considered to be an autoimmune demyelinating disease, but it has been found that MS also presents with secondary neurodegenerative pathology, including axonal loss and neuronal damage. In this review, the effects of TH on the pathogeneses of AD, PD, and MS are discussed in detail, with a focus on the following potential mechanisms: neuroprotection, neurogenesis, oxidative stress, and inflammatory response. In addition, we conduct an in-depth review of the possible clinical applications of TH, TH analogs, and thyrotropin-releasing hormone (TRH) in the treatment of AD, PD, and MS based on recent preclinical and clinical studies. By integrating experimental, clinical, and epidemiological results on the effects of TH on neurodegeneration, the present review constructs a theoretical basis for the involvement of TH in the pathogeneses of these diseases in detail. We believe that this basis will be useful for clinical diagnosis and treatment.
- Open Access
- 26 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1748648
Vitamin D as a central modulator of thyroid diseases: mechanisms and clinical implications
Thyroid diseases are common endocrine disorders, with the incidence of thyroid cancer and autoimmune thyroid diseases rising worldwide. Vitamin D, a multifunctional steroid hormone, primarily regulates bone metabolism and calcium-phosphorus homeostasis. However, recent evidence increasingly supports the hypothesis that vitamin D plays a central role in the onset and progression of thyroid disorders, including both autoimmune and non-autoimmune conditions. In the present review, we summarize the correlation between vitamin D and thyroid disorders, elucidate the anticancer and immunoregulatory mechanisms of vitamin D in thyroid diseases, and explore its role in modulating gut microbiota. Additionally, we examine the applications in clinical settings of the use of vitamin D supplements in thyroid disorders, such as a preventive measure against cancer development and progression. Clarifying the mechanisms of vitamin D action in the development and progression of thyroid disease will support the design of interventional and early therapeutic strategies that not only prevent disease onset but also serve as a secondary chemopreventive approach to halt progression and enhance thyroid function.
- 26 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1748648
Open AccessVitamin D as a central modulator of thyroid diseases: mechanisms and clinical implications
Thyroid diseases are common endocrine disorders, with the incidence of thyroid cancer and autoimmune thyroid diseases rising worldwide. Vitamin D, a multifunctional steroid hormone, primarily regulates bone metabolism and calcium-phosphorus homeostasis. However, recent evidence increasingly supports the hypothesis that vitamin D plays a central role in the onset and progression of thyroid disorders, including both autoimmune and non-autoimmune conditions. In the present review, we summarize the correlation between vitamin D and thyroid disorders, elucidate the anticancer and immunoregulatory mechanisms of vitamin D in thyroid diseases, and explore its role in modulating gut microbiota. Additionally, we examine the applications in clinical settings of the use of vitamin D supplements in thyroid disorders, such as a preventive measure against cancer development and progression. Clarifying the mechanisms of vitamin D action in the development and progression of thyroid disease will support the design of interventional and early therapeutic strategies that not only prevent disease onset but also serve as a secondary chemopreventive approach to halt progression and enhance thyroid function.
- 23 January 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (2) , e71487
Effects of Thyroid Hormones on Brain Development: Cytoarchitecture and Neurodevelopmental Disorders
Thyroid hormones (THs) are endocrine factors that play an important role in brain development by modulating several neurodevelopmental processes, including neuronal migration, synaptogenesis, and myelination. Therefore, adequate regulation of these hormones is important for the structure and function of the brain. Recently, a close association between THs deficiency or dysfunction has been found with several neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). These results imply that thyroid hormones play an important role in the occurrence of neurodevelopmental disorders. In this review, we thoroughly investigate the biosynthetic pathways and regulatory mechanisms involved in thyroid hormones production. We also assess the importance of thyroid hormones during different periods of brain development, as well as the underlying molecular processes. Finally, we extend our discussion to explore the relationship between thyroid hormones and neurodevelopmental disorders. The objective is to provide mechanistic and clinical insights and to identify promising research avenues that could facilitate earlier diagnosis and intervention for these conditions.
- 23 January 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (2) , e71487
Effects of Thyroid Hormones on Brain Development: Cytoarchitecture and Neurodevelopmental Disorders
Thyroid hormones (THs) are endocrine factors that play an important role in brain development by modulating several neurodevelopmental processes, including neuronal migration, synaptogenesis, and myelination. Therefore, adequate regulation of these hormones is important for the structure and function of the brain. Recently, a close association between THs deficiency or dysfunction has been found with several neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). These results imply that thyroid hormones play an important role in the occurrence of neurodevelopmental disorders. In this review, we thoroughly investigate the biosynthetic pathways and regulatory mechanisms involved in thyroid hormones production. We also assess the importance of thyroid hormones during different periods of brain development, as well as the underlying molecular processes. Finally, we extend our discussion to explore the relationship between thyroid hormones and neurodevelopmental disorders. The objective is to provide mechanistic and clinical insights and to identify promising research avenues that could facilitate earlier diagnosis and intervention for these conditions.
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 498-513
Dysfunctional circular RNA network in major depressive disorder: dissecting the cell identity and potential clinical applications
Circular RNAs (circRNAs), characterized by their unique covalently closed circular structure, are highly stable, conserved, and expressed in a tissue-, cell-, and developmental stage-specific manner. A lot of evidence has indicated that circRNAs play a crucial role in diversified biological and pathological processes by sponging microRNAs (miRNAs), interacting with proteins, or being translated into particular proteins, etc. Recent advancements in bioinformatics have revealed a close association between circRNAs and the development of neuropsychiatric diseases, including major depressive disorder (MDD). Increasingly, researchers emphasize the significant impact of abnormal circRNA expression and its targets on the pathogenesis of MDD. However, the detailed mechanisms involved remain elusive. Research has articulated the important role of neuronal cell dysfunction in MDD. Glia cells are the most abundant cell type in the central nervous system (CNS) and provide critical roles in MDD via intercellular-interaction–dependent pathogenic mechanisms. In this review, we extensively explore the newly identified roles of circRNAs in MDD. We summarize their novel mechanisms from cellular and molecular perspectives by deciphering how circRNAs interplay between neurons and neurogliocytes, followed by how circRNAs are tailored to synaptic plasticity and stress pathways under a variety of circumstances. Last, we discuss and predict their potential clinical values of diagnosis and therapy.
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 498-513
Dysfunctional circular RNA network in major depressive disorder: dissecting the cell identity and potential clinical applications
Circular RNAs (circRNAs), characterized by their unique covalently closed circular structure, are highly stable, conserved, and expressed in a tissue-, cell-, and developmental stage-specific manner. A lot of evidence has indicated that circRNAs play a crucial role in diversified biological and pathological processes by sponging microRNAs (miRNAs), interacting with proteins, or being translated into particular proteins, etc. Recent advancements in bioinformatics have revealed a close association between circRNAs and the development of neuropsychiatric diseases, including major depressive disorder (MDD). Increasingly, researchers emphasize the significant impact of abnormal circRNA expression and its targets on the pathogenesis of MDD. However, the detailed mechanisms involved remain elusive. Research has articulated the important role of neuronal cell dysfunction in MDD. Glia cells are the most abundant cell type in the central nervous system (CNS) and provide critical roles in MDD via intercellular-interaction–dependent pathogenic mechanisms. In this review, we extensively explore the newly identified roles of circRNAs in MDD. We summarize their novel mechanisms from cellular and molecular perspectives by deciphering how circRNAs interplay between neurons and neurogliocytes, followed by how circRNAs are tailored to synaptic plasticity and stress pathways under a variety of circumstances. Last, we discuss and predict their potential clinical values of diagnosis and therapy.
- 9 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70525
Advances in Subacute Thyroiditis: Pathogenesis, Diagnosis, and Therapies
Subacute thyroiditis (SAT) is an inflammatory thyroid disease that is often associated with viral infections. In particular, SARS‐COV‐2 and its vaccine were found to cause SAT during the recent COVID‐19 pandemic. However, the pathogenesis, clinical features, and processes still need further profiling. Recently, there are new findings and understanding about the pathogenic mechanisms of SAT. Some HLA genes have been shown to increase the risk of SAT development, and inflammatory cytokine storms could promote the progression of SAT. Some new diagnostic criteria for SAT have been proposed to facilitate clinicians' diagnosis of SAT when facing atypical symptoms in a manner of rapidity and accuracy. Plus, new treatments for SAT with herbal medicines have been proposed recently as an addition to the conventional steroidal drugs and NSAIDs. This review will provide a summary of these recent progresses of SAT on pathogenesis, diagnosis, and therapies with emphasis on the role of a variety of virus pathogens, including the COVID‐19 virus.
- 9 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70525
Advances in Subacute Thyroiditis: Pathogenesis, Diagnosis, and Therapies
Subacute thyroiditis (SAT) is an inflammatory thyroid disease that is often associated with viral infections. In particular, SARS‐COV‐2 and its vaccine were found to cause SAT during the recent COVID‐19 pandemic. However, the pathogenesis, clinical features, and processes still need further profiling. Recently, there are new findings and understanding about the pathogenic mechanisms of SAT. Some HLA genes have been shown to increase the risk of SAT development, and inflammatory cytokine storms could promote the progression of SAT. Some new diagnostic criteria for SAT have been proposed to facilitate clinicians' diagnosis of SAT when facing atypical symptoms in a manner of rapidity and accuracy. Plus, new treatments for SAT with herbal medicines have been proposed recently as an addition to the conventional steroidal drugs and NSAIDs. This review will provide a summary of these recent progresses of SAT on pathogenesis, diagnosis, and therapies with emphasis on the role of a variety of virus pathogens, including the COVID‐19 virus.